Previous 10 | Next 10 |
Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares PR Newswire DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a "modified Du...
Theravance Biopharma ( NASDAQ: TBPH ) has launched a $250M capital return program, the biopharmaceutical company announced on Monday. The firm plans to initiate a Dutch auction tender offer to purchase ~$95M of its ordinary shares in the near term. It is also looking at an...
Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program PR Newswire The Company has agreed to purchase GSK's entire holdings at $9.75 per share The Company plans to launch a Dutch auction tender offer in the near term to purchase approxim...
Royalty Pharma has agreed to acquire a royalty interest in Trelegy treatment from Innoviva, Inc. and Theravance Biopharma, Inc. for $1.3 billion in an upfront cash payment. The company is expecting this deal to add a minimum of $200 million to the adjusted non-GAAP cash receipt of RPR...
Seth Klarman’s 13F portfolio value decreased from $9.30B to $6.77B this quarter. Baupost Group added Warner Bros. Discovery and Amazon while reducing Alphabet, Intel Corp., Nexstar Media, and Verint Systems. The portfolio continues to be heavily concentrated with the top th...
Theravance Biopharma, Inc. (TBPH) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Bus...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Theravance Biopharma, Inc. 2022 Q2 - Results - Earnings Call Presentation
Theravance Biopharma press release ( NASDAQ: TBPH ): Q2 GAAP EPS of -$0.11. Revenue of $11.1M (-14.0% Y/Y). Cash, cash equivalents and marketable securities totaled $132.9 million as of June 30, 2022. 2022 Financial Guidance: Operating Expenses: The Company ex...
Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update PR Newswire Highest quarter of YUPELRI ® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (imp...
Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022 PR Newswire DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a busines...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...